What is inGenious Targeting Laboratory?
Established in 1998, inGenious Targeting Laboratory operates as a specialized service provider for the pharmaceutical and academic research communities. The company distinguishes itself through the delivery of bespoke genetically modified mouse models, a cornerstone of modern drug discovery and functional genomics. By maintaining full-service capabilities within the United States, the firm ensures rigorous quality control and intellectual property protection for its diverse client base. With a track record of over 1,650 completed projects and extensive validation in peer-reviewed literature, the organization has become a trusted partner for investigators seeking precise, genotype-specific animal models to advance their technical objectives.
How much funding has inGenious Targeting Laboratory raised?
inGenious Targeting Laboratory has raised a total of $458K across 2 funding rounds:
Debt
$150K
Debt
$308K
Debt (2020): $150K with participation from PPP
Debt (2021): $308K led by PPP
Key Investors in inGenious Targeting Laboratory
PPP
Public-Private Partnership
What's next for inGenious Targeting Laboratory?
With the recent influx of capital, inGenious Targeting Laboratory is well-positioned to scale its proprietary production methods and expand its footprint in the competitive biotech services landscape. The strategic focus will likely center on enhancing throughput for high-complexity genetic engineering projects and deepening its integration into the global drug development pipeline. As the demand for sophisticated, reliable animal models continues to rise, the company's ability to maintain its reputation for confidentiality and technical excellence will be paramount in sustaining its market leadership and driving long-term value for its stakeholders.
See full inGenious Targeting Laboratory company page
